AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02248974 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LVAD Decision Aid
Description: Decision aids are interventions or tools designed to facilitate shared decision making and patient participation in health care decisions.~This Decision Aid was designed to discuss treatment options for patients in end-stage heart failure (i.e LVAD PLACEMENT, PALLIATIVE and SUPPORTIVE CARE).
Study NCT02735356 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Applied topically
Study NCT03696888 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telecoach
Description: A skills-training web-app teaching skills for reducing problematic alcohol use.
Study NCT03696888 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TeleCoach control
Description: A web-app providing information about the health-related consequences of alcohol consumption.
Study NCT01148498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: solanezumab
Description: 400mg administered once intravenously
Study NCT00591409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sugammadex
Description: After induction of anesthesia an intubation dose of NMBA was administered IV: either 0.9 mg/kg rocuronium or 0.1 mg/kg vecuronium.~Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.04 mg/kg vecuronium IV could be administered if necessary.~At reappearance of T2 the randomized single dose of sugammadex (0.5 to 4 mg/kg) IV was administered.
Study NCT00591409 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After induction of anesthesia an intubation dose of NMBA was administered IV: either 0.9 mg/kg rocuronium or 0.1 mg/kg vecuronium.~Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.04 mg/kg vecuronium IV could be administered if necessary.~At reappearance of T2 the randomized single dose of placebo IV was administered
Study NCT05333575 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lullaby
Description: The mothers in this group were asked to sing a lullaby while their babies were fed with an orogastric tube. Mothers were released on lullabies. They were encouraged to sing the lullaby they knew or loved the most. The mother was given a sound decibel meter. Mothers were asked to do an application before going to the baby. It was taught that the number of sound decibels should not exceed 40 decibels while singing a lullaby. Later, the mother was taken to the baby's incubator at feeding time. She was seated in a chair. The working status of the decibel meter was checked and given to the mother. When the feeding started, the mother started singing lullabies and continued to sing until the feeding was finished. Attention was paid to aseptic techniques during all procedures. A single mother was asked to sing a lullaby at each feeding, and the baby of the mother who sang only a lullaby was included in the study.
Study NCT05333575 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Classic music
Description: The babies in this group were given classical music recitals during feeding. The classical music piece Mozart-Baby Smart was preferred because it was seen to be used in the literature (Keidar 2014). Mozart-Baby Smart was loaded into the music player by the researcher before the feeding process. Before feeding, the decibel meter was disinfected by surface disinfectant and placed on sterile sponge in an incubator 10 cm away from the baby's head. The music player was turned on, not exceeding 40 decibels, by adjusting the decibel meter at the time of starting the feeding, and classical music was continued during the feeding. When the feeding was finished, the music player was turned off and the incubator was taken out. Attention was paid to acetic techniques during all procedures. Ambient sounds were tried to be controlled as much as possible so that the baby would not be affected by different sounds when listening to classical music.
Study NCT03948399 — intervention group
Intervention type: DEVICE
Intervention: Duplex scanning of carotid arteries
Description: Measurement of carotid arteries
Study NCT03948399 — intervention group
Intervention type: DEVICE
Intervention: ABI measurement
Description: ankle brachial index (ABI) assessment
Study NCT02832284 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iNod System
Description: The iNod System is intended for use for diagnostic ultrasound imaging and ultrasound-guided fine needle aspiration (FNA) of extramural and submucosal lesions of the tracheobronchial tree.
Study NCT03836742 — intervention group
Intervention type: PROCEDURE
Intervention: Hemofiltration with regional citrate anticoagulation
Description: To reduce risk of metabolic alkalosis during hemofiltration treatment, ACD-A citrate solution was proposed instead of most commonly used trisodium citrate solution and relatively low target citrate concentration (2.8 mmol/L) was adopted. In case of pH increase above 7.5 or bicarbonate concentration above 40 mmol/L filtrate flow was decreased from initial 35 ml/kg/hour down to 25 ml/kg/hour which reduced bicarbonate delivery by 25%. If metabolic alkalosis persisted, the second step involved reduction of blood flow from initial 5 times down to 4 times filtrate flow, which reduced citrate flow by the same factor.
Study NCT00280020 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi Chih (TCC)
Description: Participants will learn and practice 20 movements in 1 hour sessions twice per week for 16 weeks
Study NCT00280020 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Description: For each 2-hour session held once a week for 16 weeks, the CBT treatment manual will outline objectives, patient skills, and treatment activities. Therapists will direct role-playing and other skill-development exercises that will be designed to increase patients' self-efficacy in managing their insomnia. Homework assignments will be planned weekly to ensure practice and skill application.
Study NCT00280020 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Seminar (SS)
Description: Each 2-hour session, held once a week for 16 weeks, consists of a 60-minute video presentation followed by a 60-minute question-and-answer discussion.
Study NCT01013506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IGF-1R inhibitor OSI-906
Description: Given orally
Study NCT01013506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given orally
Study NCT01013506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: goserelin
Description: Given subcutaneously
Study NCT01013506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: Given orally
Study NCT00853229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin
Description: pregabalin 150mg twice daily for 4 weeks
Study NCT02673307 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 1 chewing gum over 45 minutes
Study NCT03315234 — intervention group
Intervention type: GENETIC
Intervention: SNPs associated with CAD
Description: Genotyping will be carried out by Real-Time PCR
Study NCT02192723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Typical antipsychotic
Description: Haloperidol (6\~20mg/day) and perphenazine (16\~64mg/day), twice per day, 8 weeks
Study NCT03310294 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one bottle of placebo (minidrink fermented with low-fat milk but without Lactobacillus rhamnosus and without FOS, and without viable bacteria 90 grams)per day at breakfast until the end of the study (V5, day 140). At each visit, subjects were dispensed a sufficient amount of minidrinks until the next visit.
Study NCT03310294 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Prebiotics and Probiotics
Description: one bottle of the study product (minidrink with fermented low-fat milk added with Lactobacillus rhamnosus (Lactobacillus rhamnosus) and fructooligosaccharides (FOS),per day at breakfast until the end of the study (V5, day 140). At each visit, subjects were dispensed a sufficient amount of minidrinks until the next visit.
Study NCT04324866 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Nasopharyngeal swab
Description: Nasopharyngeal swab for the molecular diagnosis of COVID-19 infection
Study NCT03357900 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated titration of propofol and remifentanil
Description: Calculation of Consumption of propofol and remifentanil
Study NCT01996657 — intervention group
Intervention type: DRUG
Intervention: Warfarin
Study NCT02192723 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: 2\~6mg/day, twice per day, 8 weeks
Study NCT02192723 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Olanzapine, 400\~750mg/day, twice per day, 8 weeks
Study NCT02192723 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine
Description: Quetiapine, 400～750mg/day, twice per day, 8 weeks
Study NCT02519816 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous peripheral blood mononuclear cells ex vivo depleted for reactive T cells, using TH9402 based photodynamic therapy, in a final formulation of 10% DMSO, 30% autologous plasma in PlasmaLyte.
Study NCT01889355 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: AgaMatrix Blood Glucose Monitor
Study NCT04609241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD79b CAR-T Cells
Description: Each subject receive CD79b CAR-Tcells by intravenous infusion
Study NCT03669484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: Lyophilisate for preparation of solution for intravenous administration, 50 mg. Required to prepare a 50 ml syringe with the infusion solution at a concentration of 1 mg/ml (in accordance with guidance given in protocol)
Study NCT03669484 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Emulsion for infusion, 10 mg/mL in 20-mL glass vials
Study NCT03669484 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Solution for intravenous administration, 50 mg/mL. Used for anesthesia induction (at a dose of 2 mg/kg) and, if necessary, anesthesia maintenance (the dose was selected individually)
Study NCT03669484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Solution for intravenous administration, 50 mg/mL. Used for anesthesia induction (at a dose of 2 mg/kg) and, if necessary, anesthesia maintenance (the dose was selected individually)
Study NCT03669484 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium bromide
Description: Solution for intravenous administration, 10 mg/mL. Used for anesthesia induction (at a dose of 0.6-0.9 mg/kg) and, if necessary, anesthesia maintenance (the dose was selected individually)
Study NCT03669484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium bromide
Description: Solution for intravenous administration, 10 mg/mL. Used for anesthesia induction (at a dose of 0.6-0.9 mg/kg) and, if necessary, anesthesia maintenance (the dose was selected individually)
Study NCT02709681 — intervention group
Intervention type: OTHER
Intervention: Physician standard-of-care in SCD patients
Study NCT00711607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nomegestrol acetate and estradiol
Description: Group 1: one tablet of 2.5 mg NOMAC-E2 and 1.5 mg E2 per day on days 1-24 and day 35; Group 2: one tablet of 2.5 mg NOMAC-E2 and 1.5 mg E2 per day on days 1-24 followed by one Placebo tablet on day 35
Study NCT02192723 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Aripiprazole, 10～30mg/day, twice per day, 8 weeks
Study NCT02192723 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ziprasidone
Description: Ziprasidone 80\~160mg/day, twice per day, 8 weeks
Study NCT04255745 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: progressive resistance training
Description: Individual, tailored, progressive muscle strength and function intervention
Study NCT03354234 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Head up tilt (HUT)
Description: Model of -Gz: HUT up to 75 degrees (maximum)
Study NCT03354234 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower body negative pressure (LBNP)
Description: Model of -Gz: LBNP down to -100 mmHg (maximum)
Study NCT03354234 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Head down tilt (HDT)
Description: Model of +Gz: HDT down to -30 degrees (maximum)
Study NCT03354234 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tilt table
Description: Range of tilt angles: -45° to +80°, rate of tilt changes: up to 45°/s
Study NCT03354234 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LBNP chamber
Description: Range of generated underpressure: 0 to -100 mmHg, rate of underpressure changes: up to 20 mmHg/s
Study NCT02684799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenicriviroc
Study NCT02684799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Study NCT02684799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Famotidine
Study NCT01584323 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pomgranate pills
Description: Treatment arm will receive The POMx pomegranate 1,000 mg capsule a day for maximum of two weeks or until they deliver if occurs before~The POMx pomegranate 1,000 mg capsule contains at least 800 mg natural polyphenol using a pomegranate polyphenol standard and is comparable to mg/8 oz juice.(attached is confirmation Similarity of Pomegranate Juice and POMx Polyphenols)
Study NCT01584323 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pills
Description: The placebo group will receive placebo pills , for maximum of two weeks or until they deliver if occurs before The palecbo capsule contains gelatin and lactose. The capsuls are manufactured by the hospital pharmacy.All the components are medically approved fot use during pregnancy
Study NCT02714699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diclofenac potassium
Description: patients will take oral diclofenac potassium; two tablets (cataflam 25 mg) and one tablet placebo one hour before the procedure
Study NCT02714699 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hyoscine butyl bromide
Description: patients will take oral hyoscine-N- butyl bromide; 2 tablets (buscopan 10 mg) one hour before the procedure
Study NCT02714699 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: patients will take oral placebo; 2 tablets one hour before the procedure
Study NCT02877732 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EYE-SYNC eye-tracking
Description: The EYE-SYNC® portable eye-tracking system. The eye tracker is a handheld isolated display environment with embedded eye tracking sensors. The eye tracker is connected to a high-performance Windows tablet though a customized docking station. Included accessories with EYE-SYNC are a U.S. tablet power supply adapter and disposable sanitary masks. Participants are asked to follow a dot with their eyes, as the dot moves on the screen of the EYE-SYNC device.
Study NCT02877732 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EYE-SYNC eye-tracking
Description: The EYE-SYNC® portable eye-tracking system. The eye tracker is a handheld isolated display environment with embedded eye tracking sensors. The eye tracker is connected to a high-performance Windows tablet though a customized docking station. Included accessories with EYE-SYNC are a U.S. tablet power supply adapter and disposable sanitary masks. Participants are asked to follow a dot with their eyes, as the dot moves on the screen of the EYE-SYNC device.
Study NCT02877732 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SCAT-3 subtests
Description: Following subtests of SCAT-3 will be administered to the participant: Symptom, Balance, Orientation and Immediate memory
Study NCT02877732 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SCAT-3 subtests
Description: Following subtests of SCAT-3 will be administered to the participant: Symptom, Balance, Orientation and Immediate memory
Study NCT02877732 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DEM
Description: Participant will be asked to read list of numbers out loud from a card
Study NCT02877732 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DEM
Description: Participant will be asked to read list of numbers out loud from a card
Study NCT02877732 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simple Reaction Time subtest of ANAM-SRT
Description: Participants will perform Simple Reaction Time sub-test of ANAM-SRT test. They will be asked to click the mouse button every time they see an asterisk on the screen. Participants will perform ANAM-SRT 1 and ANAM-SRT 2 in this study.
Study NCT02877732 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Simple Reaction Time subtest of ANAM-SRT
Description: Participants will perform Simple Reaction Time sub-test of ANAM-SRT test. They will be asked to click the mouse button every time they see an asterisk on the screen. Participants will perform ANAM-SRT 1 and ANAM-SRT 2 in this study.
Study NCT02877732 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Level of Alertnesss
Description: Participants will answer questions. This assessment is to assess their alertness level.
Study NCT02877732 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Level of Alertnesss
Description: Participants will answer questions. This assessment is to assess their alertness level.
Study NCT04472988 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing
Description: The first session will be assigned to the assessment and the exploration of the personal history and for presenting the method to the client. Then, each case will be conceptualized according to the Model of Two Method Approach and the protocol for the treatment will be used. The procedure will be organized around targeting the most ten disturbing memories which happened before the illness debut, including stressful or traumatic memories from childhood. The rationale behind this approach is that adverse events leave traces in the neural network of an individual in such a way that these cause a variety of emotional or cognitive symptoms. If we consider the illness as being also a symptom of a traumatic past, then we expect that by accessing the dysfunctionally stored memory and stimulating the innate processing system, the symptoms of the illness diminish.
Study NCT04472988 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The participants randomised in this group will receive a protocol focused only on present and future (present symptoms, daily problems, future projects). The psychologist will lead the discussion anywhere except for the past.
Study NCT04472988 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: The participants randomised in this group will continue taking the classical treatment prescribed for Hashimoto (Levothyroxine)
Study NCT02244268 — intervention group
Intervention type: DRUG
Intervention: ALNA®
Study NCT02767518 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Description: Participants will receive an informational DVD, a pedometer, an incentive spirometer and access to the program website to help promote healthful behaviors and improved well-being in the days leading up to surgery.
Study NCT04545476 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Participants in this group will receive the experimental APIS Biomaterial on the Head.
Description: One layer of APIS® will be applied to the post-operative wound on the head covered by petrolatum impregnated gauze, a non-stick Telfa pad, gauze, and Opsite tape.
Study NCT04545476 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Participants in this group will receive the experimental APIS Biomaterial on the Lower Extremities.
Description: One layer of APIS® will be applied to the post-operative wound on the lower extremities covered by petrolatum impregnated gauze, a non-stick Telfa pad, gauze, and Opsite tape.
Study NCT04545476 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Secondary Intention Healing on the Head
Description: Participants in this group will receive standard secondary intention wound healing post-operative care on the Head. Post-operative wound will heal via conventional secondary intention. Application of petrolatum impregnated gauze, a non-stick Telfa pad, gauze, and Opsite tape.
Study NCT04545476 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Secondary Intention Healing on the Lower Extremities
Description: Participants in this group will receive standard secondary intention wound healing post-operative care on the Lower Extremities. Post-operative wound will heal via conventional secondary intention. Application of petrolatum impregnated gauze, a non-stick Telfa pad, gauze, and Opsite tape.
Study NCT02222337 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nueva Vida Intervention
Description: The psycho-educational format of the Nueva Vida Intervention is led by trained interventionists who have the survivors and caregivers go into different rooms to discuss the same topic. This format will allows them each to express their thoughts and feelings without inhibitions or concerns over how their survivor or their caregiver might respond. The specific topics for each wave of the intervention participants will be determined from a larger list of possible topics, with each group including the following core topics: Impact of Cancer on the Family, Spirituality and Cancer, Stress Management, Balancing Physical and Emotional Needs and Improving Communication.